Due to the widespread use of GLP-1R agonists to treat metabolic dysfunction, obesity, and T2DM, it remains important to understand the systemic physiology of GLP-1R activity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.